CN109170917A - The compound of creatinine in a kind of reduction blood - Google Patents
The compound of creatinine in a kind of reduction blood Download PDFInfo
- Publication number
- CN109170917A CN109170917A CN201811123115.4A CN201811123115A CN109170917A CN 109170917 A CN109170917 A CN 109170917A CN 201811123115 A CN201811123115 A CN 201811123115A CN 109170917 A CN109170917 A CN 109170917A
- Authority
- CN
- China
- Prior art keywords
- creatinine
- urea
- compound
- probiotics
- uric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 title claims abstract description 148
- 229940109239 creatinine Drugs 0.000 title claims abstract description 75
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 210000004369 blood Anatomy 0.000 title claims abstract description 20
- 239000008280 blood Substances 0.000 title claims abstract description 20
- 230000009467 reduction Effects 0.000 title description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 83
- 239000004202 carbamide Substances 0.000 claims abstract description 43
- 239000006041 probiotic Substances 0.000 claims abstract description 26
- 235000018291 probiotics Nutrition 0.000 claims abstract description 26
- 229920001202 Inulin Polymers 0.000 claims abstract description 17
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 17
- 229940029339 inulin Drugs 0.000 claims abstract description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 16
- 230000003907 kidney function Effects 0.000 claims abstract description 16
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims description 32
- 210000002700 urine Anatomy 0.000 claims description 21
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 11
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 11
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 244000298479 Cichorium intybus Species 0.000 claims description 2
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 42
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 42
- 229940116269 uric acid Drugs 0.000 abstract description 42
- 229940045136 urea Drugs 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 12
- 230000000630 rising effect Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 description 8
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 8
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 8
- -1 10g through crushing Chemical compound 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of compounds for reducing blood creatinine, contain edible inulin, glutamine and probiotics.Ingredient in compound of the present invention is without side-effects, creatinine in blood, uric acid and urea content can be significantly reduced in a short time, creatinine excessively high in blood, uric acid and urea can be alleviated significantly, the filter effect of renal function tends to be good, renal function rises, so that renal function relevant to creatinine, urea, uric acid content rising rises, there is good clinical meaning and medical value.
Description
Technical field
The invention belongs to non-medical treatment field, in particular to a kind of compound for reducing creatinine in blood.
Background technique
Creatinine is the product of human muscle's metabolism.In the muscle of human body, creatine is mainly dehydrated by irreversible non-enzymatic
Reaction gently forms creatinine, then is discharged into blood, with homaluria.Therefore the height of serum creatinine content and internal muscle total amount
Correlation in close relations, not vulnerable to food effect.Creatinine is small-molecule substance, can be filtered by glomerulus ball, in renal tubule very
It can be absorbed again less, the creatinine generated in vivo daily, almost all is excreted with urine, and is not influenced by urine volume generally.
Not identical as creatinine clearance rate, creatinine clearance rate is more sensitive compared with serum creatinine.It is (compensatory in renal hypofunction early stage
Phase), creatinine clearance rate declines and serum creatinine is normal.When glomerular filtration rate drops to normal 50% or more, serum creatinine
Just start to increase rapidly, therefore when serum creatinine is apparently higher than normal, often indicates that renal function seriously damages.Since creatinine is removed
Rate is also influenced by glomerulus concentrating function, and in the case where kidney concentrating function is impaired, serum creatinine is exactly to reflect glomerulus function
The most reliability index of energy.
Serum creatinine height represents glomerular filtration rate and the decline of kidney functions of expelling toxin.At this point, the renal function of nephrotic starts
Damage, into the stage of renal insufficiency.And with the continual raising of serum creatinine index, the renal impairment degree of patient
It will be increasingly severe.The creatinine of normal person is between 40~120.If creatinine is more than this range, patient has entered kidney
Pathological process, it is serious to develop into uremia.Hospitals at Present reduces in blood in the scheme of creatinine, using haemodialysis.This side
Case has human body damaging, is carried out by the method that penetration and plasma ion exchange.Therefore a kind of energy drop is developed
The compound of creatinine in low blood can overcome the disadvantages that deficiency clinically, and promote application of the compound in treatment of kidney disease.
Summary of the invention
The primary purpose of the present invention is that providing a kind of compound for reducing creatinine in blood.
The technical solution used in the present invention is:
The compound of creatinine in a kind of reduction blood, including glutamine, inulin and probiotics.
Further, glutamine, inulin and the amount ratio of probiotics are as follows: 20~80g:5~25g:500~150,000,000,000
A activity bacterium number.
Further, glutamine, inulin and the amount ratio of probiotics are as follows: 40~60g:10~20g:800~1200
Hundred million active bacterium numbers.
Further, probiotics is at least one of bifidobacterium lactis, lactobacillus acidophilus and Lactobacillus rhamnosus.
Further, in probiotics bifidobacterium lactis, lactobacillus acidophilus and the active bacterium number of Lactobacillus rhamnosus be 250~
750:125~380:125~380.
Further, the glutamine is L-Glutamine.
Further, inulin is to be crushed by witloof, is dry, decolourizing to extract.
Compound described above reduces the application in blood creatinine product in preparation.
The application of compound described above in preparation prevention or/and treatment decreased renal function product.
Further, the treatment decreased renal function is under renal function relevant to creatinine, urea, uric acid content rising
Drop.
Further, the product includes medical food, functional food, nutrient.
The beneficial effects of the present invention are:
Ingredient in compound of the present invention is without side-effects, is made of edible inulin, probiotics and glutamine；
Creatinine excessively high in blood, uric acid and urea can be substantially reduced in a short time, and significant effect is obtained in treatment crowd
Fruit, effective percentage reach 87%, have good clinical meaning and medical value.
Specific embodiment
The present invention is further illustrated combined with specific embodiments below.
Embodiment 1
A kind of compound reducing creatinine, inulin, 40g l-GLUTAMINE including 10g through crushing, drying and decoloration with
And the probiotics of 80,000,000,000 active bacterium numbers, the wherein bifidobacterium lactis comprising 40,000,000,000 active bacterium numbers in probiotics, 20,000,000,000
The Lactobacillus rhamnosus of the lactobacillus acidophilus of active bacterium number and 20,000,000,000 active bacterium numbers.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detects creatinine, urea, uric acid index.
Embodiment 2
A kind of compound reducing creatinine, inulin, 60g l-GLUTAMINE including 20g through crushing, drying and decoloration with
And the probiotics of 120,000,000,000 active bacterium numbers, the wherein bifidobacterium lactis comprising 60,000,000,000 active bacterium numbers in probiotics, 35,000,000,000
The lactobacillus acidophilus of a activity bacterium number and the Lactobacillus rhamnosus of 25,000,000,000 active bacterium numbers.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detects creatinine, urea, uric acid index.
Embodiment 3
A kind of compound reducing creatinine, inulin, 50g l-GLUTAMINE including 15g through crushing, drying and decoloration with
And the probiotics of 100,000,000,000 active bacterium numbers, the wherein bifidobacterium lactis comprising 50,000,000,000 active bacterium numbers in probiotics, 25,000,000,000
The lactobacillus acidophilus of a activity bacterium number and the Lactobacillus rhamnosus of 25,000,000,000 active bacterium numbers.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detects creatinine, urea, uric acid index.
Embodiment 4
It is a kind of reduce creatinine compound, including 5g through crushing, drying and decoloration inulin, 20g l-GLUTAMINE and
The probiotics of 50000000000 active bacterium numbers, the wherein bifidobacterium lactis comprising 25,000,000,000 active bacterium numbers in probiotics, 12,500,000,000 work
Property the lactobacillus acidophilus of the bacterium number and Lactobacillus rhamnosus of 12,500,000,000 active bacterium numbers.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detects creatinine, urea, uric acid index.
Embodiment 5
It is a kind of reduce creatinine compound, including 25g through crushing, drying and decoloration inulin, 80g l-GLUTAMINE and
The probiotics of 150000000000 active bacterium numbers, the wherein bifidobacterium lactis comprising 75,000,000,000 active bacterium numbers in probiotics, 37,500,000,000
The Lactobacillus rhamnosus of the lactobacillus acidophilus of active bacterium number and 37,500,000,000 active bacterium numbers.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detects creatinine, urea, uric acid index.
Comparative example 1
A kind of compound reducing creatinine, the probiotics including 50g l-GLUTAMINE and 100,000,000,000 active bacterium numbers,
Wherein the bifidobacterium lactis comprising 50,000,000,000 active bacterium numbers in probiotics, 25,000,000,000 active bacterium numbers lactobacillus acidophilus and 250
The Lactobacillus rhamnosus of hundred million active bacterium numbers.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detect creatinine, urea, uric acid index, discovery index does not have significant change.
Comparative example 2
A kind of compound reducing creatinine, including 15g is through crushing, drying and decoloration inulin and 100,000,000,000 active bacterium numbers
Probiotics, the wherein bifidobacterium lactis comprising 50,000,000,000 active bacterium numbers in probiotics.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detect creatinine, urea, uric acid index, discovery index does not have significant change.
Comparative example 3
A kind of compound reducing creatinine, including 15g is through crushing, drying and decoloration inulin and 50g l-GLUTAMINE.
Before patient takes compound of the present invention, urine detection creatinine, urea, uric acid index have been acquired.It is taken to patient
After compound 45 days, then urine is acquired, detect creatinine, urea, uric acid index, discovery index does not have significant change.
The pretherapy and post-treatment index variation of 1 patient of table
The data of urea, uric acid are it is found that the urea of Cai is reduced to 11.2mmol/L from 16.3mmol/L from table 1, urine
Acid is also reduced to 320 μm of ol/L, significant effect from 384 μm of ol/L from having intervened 46 days；The urea of Huang subtracts from 16.6mmol/L
10.3mmol/L is arrived less, and uric acid drops to 290 μm of ol/L from 319 μm of ol/L after treatment.The urea of history from
12.2mmol/L is reduced to 8.01mmol/L, and uric acid is also reduced to 189 μm of ol/L from 211 μm of ol/L from having intervened 46 days；Liang
Urea be reduced to 8.4mmol/L from 9.5mmol/L, uric acid is also reduced to 196 μm of ol/ from 198 μm of ol/L from having intervened 46 days
L；Week, the urea of certain reduced 6mmol/L from 6.6mmol/L, and uric acid is also reduced to 167 μ from 189 μm of ol/L from having intervened 46 days
mol/L.After these data proof has taken health care product prepared by the present invention, the urea of patient, uric acid content decline, renal function
Filter effect tends to well, and renal function rises, so that renal function rising relevant to creatinine, urea, uric acid content risings.Comparison
Health care product prepared by the present invention is not taken, the content of urea and uric acid is not remarkably decreased.
In addition, the content of creatinine is declined in blood after patient has taken compound of the invention.Wherein creatinine declines
Percentage it is relatively high, history drops to 91 μm of ol/L from 267 μm of ol/L, and down ratio highest 66%, creatinine content is in short-term
Interior to decline to a great extent, intervention time is 38 days；Week, certain from 310 μm of ol/L dropped to 129 μm of ol/L, creatinine be in 38 days substantially under
Drop, ratio reach 58%.Liang drops to 132 from 313, declines to a great extent in 51 days, ratio 58%, significant effect.Before treatment
Significant change afterwards is had effect taking product of the invention, it was demonstrated that the significant effect of present invention reduction serum creatinine.
Typical case
(1) poplar, male, 88 years old, the creatinine content of blood was 505 μm of ol/L when going to a doctor, and urea and uric acid are in normal range (NR)
Interior, urea 49.4mmol/L, uric acid is 361 μm of ol/L, and after being taken compound object prepared by the present invention, creatinine is fallen to after 40 days
301 μm of ol/L, have dropped very significantly.People digest road symptom: food intake difference makes moderate progress；Skin itching is mitigated.
(2) week certain, female, 52 years old, go to a doctor when blood creatinine content be 403 μm of ol/L, urea and uric acid are in higher number
It is worth in range, urea 18.3mmol/L, uric acid is 453 μm of ol/L, after being taken compound object prepared by the present invention, creatinine after 40 days
199 μm of ol/L are fallen to, the numerical value of nearly half is had dropped, creatinine is eased.Urea and uric acid drop in normal range (NR), urine
Element is 9.6mmol/L, and uric acid is 339 μm of ol/L, and renal function mentions rising.
(3) Situ, male, 77 years old, the creatinine content of blood was 422 μm of ol/L when going to a doctor, and urea and uric acid are higher
In numberical range, urea 7.3mmol/L, uric acid is 293 μm of ol/L, after being taken compound object prepared by the present invention, flesh after 45 days
Acid anhydride falls to 213 μm of ol/L, has dropped the numerical value of nearly half, and creatinine is eased.Urea and uric acid drop in normal range (NR),
Urea is 6.5mmol/L, and uric acid is 207 μm of ol/L.Patient's food intake difference makes moderate progress；Skin itching is mitigated.
(4) history, female, 83 years old, the creatinine content of blood was 267 μm of ol/L when going to a doctor, and urea and uric acid are in higher number
It is worth in range, urea 12.2mmol/L, uric acid is 211 μm of ol/L, after being taken compound object prepared by the present invention, creatinine after 38 days
91 μm of ol/L are fallen to, 2/3rds numerical value is had dropped, creatinine content is eased.Urea is reduced to 8.01mmol/L, uric acid
For 189 μm of ol/L.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present invention,
It should be equivalent substitute mode, be included within the scope of the present invention.
Claims (10)
1. a kind of compound for reducing creatinine in blood, which is characterized in that including glutamine, inulin and probiotics.
2. compound according to claim 1, which is characterized in that glutamine, inulin and the amount ratio of probiotics are as follows:
20~80g:5~25g:500~150,000,000,000 active bacterium number.
3. compound according to claim 2, which is characterized in that glutamine, inulin and the amount ratio of probiotics are as follows:
40~60g:10~20g:800~120,000,000,000 active bacterium number.
4. described in any item compounds according to claim 1~3, which is characterized in that probiotics is bifidobacterium lactis, acidophilus cream
At least one of bacillus and Lactobacillus rhamnosus.
5. described in any item compounds according to claim 1~3, which is characterized in that bifidobacterium lactis, acidophilus cream in probiotics
The active bacterium number of bacillus and Lactobacillus rhamnosus is 250~75,000,000,000: 125~37,500,000,000: 125~37,500,000,000.
6. described in any item compounds according to claim 1~3, which is characterized in that inulin is to be crushed by witloof, is dry, de-
Color extracts.
7. the described in any item compounds of claim 1~6 reduce the application in blood creatinine product in preparation.
8. the described in any item compounds of claim 1~6 answering in preparation prevention or/and treatment decreased renal function product
With.
9. application according to claim 8, which is characterized in that the treatment decreased renal function be and creatinine, urea, urine
Acid content rises relevant decreased renal function.
10. application according to claim 7 or 8, which is characterized in that the product include medical food, functional food,
Nutrient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811123115.4A CN109170917A (en) | 2018-09-26 | 2018-09-26 | The compound of creatinine in a kind of reduction blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811123115.4A CN109170917A (en) | 2018-09-26 | 2018-09-26 | The compound of creatinine in a kind of reduction blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109170917A true CN109170917A (en) | 2019-01-11 |
Family
ID=64906348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811123115.4A Pending CN109170917A (en) | 2018-09-26 | 2018-09-26 | The compound of creatinine in a kind of reduction blood |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109170917A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114271504A (en) * | 2021-12-31 | 2022-04-05 | 桂林古膳食品科技有限公司 | Application of composite dietary fiber in preparation of product for reducing serum uremia toxin and improving kidney function |
| CN115429820A (en) * | 2022-05-16 | 2022-12-06 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170106029A1 (en) * | 2002-03-13 | 2017-04-20 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
-
2018
- 2018-09-26 CN CN201811123115.4A patent/CN109170917A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170106029A1 (en) * | 2002-03-13 | 2017-04-20 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
Non-Patent Citations (1)
| Title |
|---|
| 熊文等: "双歧杆菌与乳酸杆菌在肾衰大鼠胃肠道不同部位的定植及其对小分子毒素的分解", 《中南大学学报(医学版)》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114271504A (en) * | 2021-12-31 | 2022-04-05 | 桂林古膳食品科技有限公司 | Application of composite dietary fiber in preparation of product for reducing serum uremia toxin and improving kidney function |
| CN115429820A (en) * | 2022-05-16 | 2022-12-06 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5141927A (en) | Antihypertensive preparation comprising an alginate and vitamin D | |
| JP5230431B2 (en) | Method for lowering blood pressure in individuals with prehypertension and / or individuals with metabolic syndrome | |
| JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| CN109170917A (en) | The compound of creatinine in a kind of reduction blood | |
| CN107136506A (en) | A kind of Black Box Tracing piece with blood pressure reduction effect and preparation method thereof | |
| EP3861866A1 (en) | Composition comprising molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease | |
| CN105211849A (en) | A kind of health food of prevention and therapy diabetes | |
| CN107050073A (en) | It is a kind of to strengthen memory, the health products for slowing down brain aging and preparation method thereof | |
| CN112770749A (en) | Application of combination of bifidobacterium and berberine in treating pre-diabetes and type 2 diabetes | |
| CN101406544A (en) | Rosa roxburghii oral liquid and preparation method thereof | |
| JP4813023B2 (en) | Health foods and drugs | |
| CN111227240A (en) | Meal replacement powder with blood sugar reducing effect and preparation method and application thereof | |
| CN109125361A (en) | A kind of compound reducing the gentle solution acute gout arthritis symptom of high lithemia | |
| Murakami et al. | Beneficial Effect of Honeybee-collected Pollen Lump Extract on Benign Prostatic Hyperplasia (BPH)—A Double-blind, Placebo-controlled Clinical Trial— | |
| KR102080128B1 (en) | NAFLD / NASH Prevention and / or Treatment | |
| KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
| JP6088071B2 (en) | Serum uric acid lowering agent containing rice protein as active ingredient | |
| CN107693732A (en) | A kind of pharmaceutical composition for treating hypertensive nephropathy and preparation method thereof | |
| CN106857994A (en) | A kind of health-care pine needle tea and preparation method thereof | |
| RU2538086C2 (en) | Method of treating diabetes mellitus, complicated by accompanying diseases | |
| CN106620012A (en) | Green plum enzyme nutrient liquid and preparation method thereof | |
| CN105995971A (en) | Nutritional liquid food for promoting diabetes recovery and preparation method thereof | |
| Pramono et al. | Natrium dischargement from peripheral blood as a predominant factor influenced by the administration of banana (Musa paradisiaca) on elderly female hypertensive patient | |
| CN110584123A (en) | Xylan polysaccharide iron compound, preparation method and application thereof | |
| CN110051851A (en) | A kind of combination of sodium-glucose co-transporter -2 inhibitor and maniod ebish flower extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190111 |
|
| RJ01 | Rejection of invention patent application after publication |